Sei Investments Co. Has $143.21 Million Stock Holdings in Stryker Co. (NYSE:SYK)

Sei Investments Co. trimmed its holdings in shares of Stryker Co. (NYSE:SYK) by 0.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 397,758 shares of the medical technology company’s stock after selling 258 shares during the quarter. Sei Investments Co.’s holdings in Stryker were worth $143,211,000 as of its most recent filing with the SEC.

Other hedge funds have also bought and sold shares of the company. Chicago Capital LLC increased its position in Stryker by 3.1% during the fourth quarter. Chicago Capital LLC now owns 195,052 shares of the medical technology company’s stock worth $70,228,000 after acquiring an additional 5,841 shares during the period. Zhang Financial LLC increased its position in Stryker by 55.0% during the fourth quarter. Zhang Financial LLC now owns 114,889 shares of the medical technology company’s stock worth $41,366,000 after acquiring an additional 40,784 shares during the period. Appleton Partners Inc. MA increased its position in Stryker by 5.0% during the fourth quarter. Appleton Partners Inc. MA now owns 29,222 shares of the medical technology company’s stock worth $10,521,000 after acquiring an additional 1,400 shares during the period. Metis Global Partners LLC increased its position in Stryker by 10.2% during the fourth quarter. Metis Global Partners LLC now owns 16,841 shares of the medical technology company’s stock worth $6,064,000 after acquiring an additional 1,561 shares during the period. Finally, US Bancorp DE increased its position in Stryker by 0.5% during the fourth quarter. US Bancorp DE now owns 182,825 shares of the medical technology company’s stock worth $65,829,000 after acquiring an additional 976 shares during the period. 77.09% of the stock is owned by institutional investors.

Analysts Set New Price Targets

SYK has been the topic of a number of recent research reports. Wells Fargo & Company raised their price target on shares of Stryker from $427.00 to $435.00 and gave the stock an “overweight” rating in a research report on Wednesday, January 29th. Needham & Company LLC reissued a “buy” rating and issued a $442.00 target price on shares of Stryker in a report on Friday. Morgan Stanley raised shares of Stryker from an “equal weight” rating to an “overweight” rating and raised their target price for the company from $370.00 to $445.00 in a report on Monday, December 2nd. Truist Financial raised their target price on shares of Stryker from $409.00 to $413.00 and gave the company a “hold” rating in a report on Thursday, January 30th. Finally, Citigroup reissued a “buy” rating and issued a $450.00 target price on shares of Stryker in a report on Wednesday, February 26th. Five equities research analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company. According to MarketBeat.com, Stryker has an average rating of “Moderate Buy” and a consensus target price of $421.90.

Insider Buying and Selling

In other news, Director Ronda E. Stryker sold 201,392 shares of the business’s stock in a transaction that occurred on Friday, January 31st. The shares were sold at an average price of $392.24, for a total value of $78,993,998.08. Following the transaction, the director now owns 3,642,075 shares in the company, valued at approximately $1,428,567,498. The trade was a 5.24 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Allan C. Golston sold 2,458 shares of the business’s stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $383.07, for a total transaction of $941,586.06. Following the completion of the transaction, the director now owns 14,895 shares in the company, valued at $5,705,827.65. This trade represents a 14.16 % decrease in their position. The disclosure for this sale can be found here. 5.90% of the stock is owned by corporate insiders.

Stryker Stock Down 0.8 %

NYSE:SYK opened at $371.38 on Friday. The firm’s 50 day simple moving average is $384.28 and its 200 day simple moving average is $373.93. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.95 and a quick ratio of 1.32. Stryker Co. has a one year low of $314.93 and a one year high of $406.19. The company has a market cap of $141.71 billion, a PE ratio of 47.86, a P/E/G ratio of 2.93 and a beta of 0.95.

Stryker (NYSE:SYK) last posted its earnings results on Tuesday, January 28th. The medical technology company reported $4.01 EPS for the quarter, topping the consensus estimate of $3.87 by $0.14. Stryker had a net margin of 13.25% and a return on equity of 23.58%. During the same quarter in the prior year, the firm posted $3.46 EPS. On average, research analysts anticipate that Stryker Co. will post 13.47 earnings per share for the current year.

Stryker Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, April 30th. Investors of record on Monday, March 31st will be given a dividend of $0.84 per share. The ex-dividend date of this dividend is Monday, March 31st. This represents a $3.36 annualized dividend and a yield of 0.90%. Stryker’s dividend payout ratio is presently 43.30%.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.